Table 2 Clinical outcome according to... | American Society of Hematology

Table 2

Clinical outcome according to BAALC expression in BCR-ABL⁻ and MLL-AF4⁻ patients

Clinical outcome	BAALC T1 (n = 94)	BAALC T2 (n = 67)	BAALC T3 (n = 41)	P
Complete remission, no./total (%) (n = 193)	86/92 (94)	59/65 (91)	29/36 (81)	.09‡
Refractory disease, no./total (%) (n = 184)	1/87 (1)	4/63 (6)	5/34 (15)	.009
Overall survival at 5 y, percentage (95% CI) (n = 202)*	70 (59-81)	52 (36-67)	38 (22-54)	.004
Relapse rate, no./total (%) (n = 114)†	26/53 (49)	16/36 (44)	10/25 (40)	.76

Clinical outcome	BAALC T1 (n = 94)	BAALC T2 (n = 67)	BAALC T3 (n = 41)	P
Complete remission, no./total (%) (n = 193)	86/92 (94)	59/65 (91)	29/36 (81)	.09‡
Refractory disease, no./total (%) (n = 184)	1/87 (1)	4/63 (6)	5/34 (15)	.009
Overall survival at 5 y, percentage (95% CI) (n = 202)*	70 (59-81)	52 (36-67)	38 (22-54)	.004
Relapse rate, no./total (%) (n = 114)†	26/53 (49)	16/36 (44)	10/25 (40)	.76

Patients who received SCT in CR1 were censored at the time of transplantation.

Patients who received SCT in CR1 were excluded.

P value across the 3 BAALC tertiles. Statistical significance was reached comparing BAALC T1 vs T3 (P = .047).